Literature DB >> 8260377

Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

R García1, J M Hernández, M D Caballero, M González, J Galende, M C del Cañizo, L Vázquez, J F San Miguel.   

Abstract

The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH > 320 U ml-1, age > 45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase > 190 UI dl and ESR > 40 mm h. In addition, Hb < 12.5 gr dl-1 and abdominal disease were statistically relevant for CR while a poor performance score (ECOG > or = 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH > 320 U ml-1 had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses. According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and stage) a predictive model was established that allows the stratification of patients into two prognostic groups: one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the present study shows that LDH is one of the most important prognostic factors in HD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260377      PMCID: PMC1968658          DOI: 10.1038/bjc.1993.509

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation.

Authors:  J G Gribben; D C Linch; C R Singer; A K McMillan; M Jarrett; A H Goldstone
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

2.  The second chance for advanced Hodgkin's disease.

Authors:  G P Canellos
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

Review 3.  Hodgkin's disease.

Authors:  W J Urba; D L Longo
Journal:  N Engl J Med       Date:  1992-03-05       Impact factor: 91.245

4.  Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease.

Authors:  N Villamor; J C Reverter; J M Martí; E Montserrat; C Rozman
Journal:  Eur J Haematol       Date:  1991-01       Impact factor: 2.997

5.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

6.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

7.  Prognostic factors in Hodgkin's disease stage IV.

Authors:  L Specht; N I Nissen
Journal:  Eur J Haematol       Date:  1988-10       Impact factor: 2.997

8.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.

Authors:  D J Straus; J J Gaynor; J Myers; D P Merke; J Caravelli; D Chapman; J Yahalom; B D Clarkson
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

9.  Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.

Authors:  J Yahalom; S Gulati
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

10.  The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.

Authors:  C E Desch; M R Lasala; T J Smith; B E Hillner
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

View more
  15 in total

1.  Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

Authors:  Kuniaki Itoh; Tomohiro Kinoshita; Takashi Watanabe; Kenichi Yoshimura; Rumiko Okamoto; Takaaki Chou; Michinori Ogura; Masami Hirano; Hideki Asaoku; Mitsutoshi Kurosawa; Yoshiharu Maeda; Ken Omachi; Yukiyoshi Moriuchi; Masaharu Kasai; Kazunori Ohnishi; Nobuyuki Takayama; Yasuo Morishima; Kensei Tobinai; Harumi Kaba; Seiichiro Yamamoto; Haruhiko Fukuda; Masahiro Kikuchi; Tadashi Yoshino; Yoshihiro Matsuno; Tomomitsu Hotta; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2010-03-03       Impact factor: 2.490

Review 2.  Investigation of NK cell function and their modulation in different malignancies.

Authors:  Gordana Konjevic; Vladimir Jurisic; Viktor Jovic; Ana Vuletic; Katarina Mirjacic Martinovic; Sandra Radenkovic; Ivan Spuzic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.

Authors:  Jian Chen; Meng-xiong Sun; Ying-qi Hua; Zheng-dong Cai
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-31       Impact factor: 4.553

4.  Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Janina Kaminska; Jan Walewski
Journal:  Med Oncol       Date:  2011-06-30       Impact factor: 3.064

5.  Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.

Authors:  Ying-Jie Zhu; Yue-Li Sun; Yi Xia; Wen-Qi Jiang; Jia-Jia Huang; Hui-Qiang Huang; Tong-Yu Lin; Zhong-Zhen Guan; Zhi-Ming Li
Journal:  Med Oncol       Date:  2011-03-10       Impact factor: 3.064

Review 6.  The multiple roles of LDH in cancer.

Authors:  Giuseppina Claps; Sara Faouzi; Virginie Quidville; Feras Chehade; Shensi Shen; Stéphan Vagner; Caroline Robert
Journal:  Nat Rev Clin Oncol       Date:  2022-10-07       Impact factor: 65.011

7.  Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.

Authors:  Enrique González-Billalabeitia; Ricardo Hitt; Jesús Fernández; Esther Conde; Francisco Martínez-Tello; Rafael Enríquez de Salamanca; Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

8.  Clinical Profile and Chemotherapy Response in Children with Hodgkin Lymphoma at a Tertiary Care Centre.

Authors:  Rachna Seth; Rashmi Ranjan Das; Kirti Puri; Prashant Singh
Journal:  J Clin Diagn Res       Date:  2015-11-01

9.  Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma.

Authors:  Jing Ma; Yafei Wang; Haifeng Zhao; Su Liu; Qian Li; Li Lin; Yuanfang Yue; Xiaofang Wang; Zhigang Zhao; Yong Yu; Yizhuo Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

10.  Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy.

Authors:  Paul J Akhenblit; Mark D Pagel
Journal:  J Cancer Sci Ther       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.